Literature DB >> 24815603

Animal models of Epstein Barr virus infection.

Bithi Chatterjee1, Carol Sze Leung1, Christian Münz2.   

Abstract

Epstein Barr virus (EBV) was the first human tumor virus to be identified. Despite 50years of research on this oncogenic virus, no therapeutic or prophylactic vaccine is available against this pathogen. In part, the development of such a vaccine is hampered by the lack of in vivo models for EBV infection and immune control. However, with the advent of mice with reconstituted human immune system components (HIS mice), certain aspects of EBV associated diseases and immune responses can be modeled in vivo. In this review, we will discuss the insights that can be gained from these experiments, and how immune system components can be manipulated to interrogate their function during EBV infection. Finally, we will compare EBV immunobiology in HIS mice to infection by EBV-related viruses in monkeys, and we will outline the strengths and weaknesses of these two in vivo models of EBV infection. Both of these models show great promise as a platform for preclinical EBV vaccine testing.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dendritic cells; Humanized mice; Infectious mononucleosis; Lymphoproliferative disease; NK cells; T cells

Mesh:

Year:  2014        PMID: 24815603     DOI: 10.1016/j.jim.2014.04.009

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  11 in total

Review 1.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

2.  An immunocompetent patient with a recurrence-free Epstein-Barr virus positive plasmacytoma possesses robust Epstein-Barr virus specific T-cell responses.

Authors:  Bithi Chatterjee; Laura Sahli; Obinna Chijioke; Philip Went; Christian Münz; Andreas Trojan
Journal:  Haematologica       Date:  2017-07-13       Impact factor: 9.941

3.  A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice.

Authors:  Javier Gordon Ogembo; Matthew R Muraswki; Lori W McGinnes; Agapi Parcharidou; Rujapak Sutiwisesak; Timelia Tison; Juan Avendano; Deep Agnani; Robert W Finberg; Trudy G Morrison; Joyce D Fingeroth
Journal:  J Transl Med       Date:  2015-02-06       Impact factor: 5.531

Review 4.  Study of viral pathogenesis in humanized mice.

Authors:  Jenna M Gaska; Alexander Ploss
Journal:  Curr Opin Virol       Date:  2015-01-22       Impact factor: 7.090

5.  Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice.

Authors:  Christopher B Whitehurst; Guangming Li; Stephanie A Montgomery; Nathan D Montgomery; Lishan Su; Joseph S Pagano
Journal:  mBio       Date:  2015-10-20       Impact factor: 7.867

Review 6.  Status of Epstein-Barr Virus Coinfection with Helicobacter pylori in Gastric Cancer.

Authors:  Shyam Singh; Hem Chandra Jha
Journal:  J Oncol       Date:  2017-03-21       Impact factor: 4.375

7.  Deoxynivalenol- and zearalenone-contaminated feeds alter gene expression profiles in the livers of piglets.

Authors:  Kondreddy Eswar Reddy; Jin Young Jeong; Yookyung Lee; Hyun-Jeong Lee; Min Seok Kim; Dong-Wook Kim; Hyun Jung Jung; Changyong Choe; Young Kyoon Oh; Sung Dae Lee
Journal:  Asian-Australas J Anim Sci       Date:  2017-08-16       Impact factor: 2.509

8.  Uncovering early events in primary Epstein-Barr virus infection using a rabbit model.

Authors:  Narendran Reguraman; Asma Hassani; Pretty Philip; Gulfaraz Khan
Journal:  Sci Rep       Date:  2021-10-27       Impact factor: 4.379

Review 9.  The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development.

Authors:  Cong Sun; Xin-Chun Chen; Yin-Feng Kang; Mu-Sheng Zeng
Journal:  Front Immunol       Date:  2021-06-08       Impact factor: 7.561

Review 10.  Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.

Authors:  Xinle Cui; Clifford M Snapper
Journal:  Front Immunol       Date:  2021-10-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.